Medirox was formed in 1998 from a merger of Global Haemostasis Institute – a research company located at Linköping University Hospital – together with IL Scandinavia AB and BioMed AB, two of the major Scandinavian distributors within the haemostasis field. The company was at the time listed on the NGM stock market in Stockholm, and a little later – in year 2000 – the manufactury of well-known reagent manufacturer Chromogenix AB was incorporated as well, bringing together research, development, and production under one roof.
During the start-up years Medirox went through a number of organisation and structural changes, before finding the current set up in 2008. The company has since been very successful and was in 2011 named as the “Life Science company of the year” by premium Swedish financial press Dagens Industri. Current set up includes a headquarter holding production and administration in Studsvik, Nyköping, an R&D center at Linköping’s University hospital and a sale & marketing office in central Stockholm.
Medirox currently consists of 20 employees serving more than 60 internationally spread customers.
In October 2016 Ahead Global LTD announced a mandatory offer to shareholders to buy the whole company and started the process to unlist it from public list Aktietorget. The process was finalised in 2017.